| 000 | 02601nam a2200409 i 4500 | ||
|---|---|---|---|
| 999 |
_c361304 _d361304 |
||
| 001 | 361304 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102121339.0 | ||
| 006 | a|||| o|||| 00| 0 | ||
| 007 | cr nn nnnaamaa | ||
| 008 | 211011s2021 sz | o |||| 0|eng d | ||
| 020 | _a9783030873240 | ||
| 024 | 7 |
_a10.1007/978-3-030-87324-0 _2doi |
|
| 040 |
_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC |
||
| 050 | 4 |
_aRA644.C67 _b2021 EB |
|
| 100 | 1 |
_aFocosi, Daniele _eautor _0(orcid)0000-0001-8811-195X _1https://orcid.org/0000-0001-8811-195X _4aut _4http://id.loc.gov/vocabulary/relators/aut _9101702 |
|
| 245 | 1 | 0 |
_aSARS-CoV-2 Spike Protein Convergent Evolution : _bImpact of Virus Variants on Efficacy of COVID-19 Therapeutics and Vaccines _cby Daniele Focosi |
| 250 | _aFirst edition 2021 | ||
| 264 | 1 |
_aCham _bSpringer International Publishing _c2021 |
|
| 300 |
_a1 recurso en línea (XIII, 136 páginas) _b11 ilustraciones, 2 ilustraciones a color |
||
| 336 |
_2rdacontent _aTexto _btxt |
||
| 337 |
_2rdamedia _aelectrónico _bc |
||
| 338 |
_2rdacarrier _arecurso electrónico _bcr |
||
| 347 |
_aArchivo de texto _bPDF |
||
| 490 | 0 |
_aSpringerBriefs in Microbiology _x2191-5393 |
|
| 490 | 0 | _aBiomedical and Life Sciences (SpringerNature-11642) | |
| 490 | 0 | _aBiomedical and Life Sciences (R0) (SpringerNature-43708) | |
| 505 | 0 | _aChapter 1. Why the Spike protein is relevant for COVID19 therapeutics -- Chapter 2. SARS-CoV-2 variants -- Chapter 3. Conclusion. | |
| 520 | 3 | _aThis book reviews the current knowledge of the globally circulating SARS-CoV-2 variants, highlights their distinct genetic characteristics and associated conformational changes in the viral spike protein, and profoundly discusses the mechanisms of convergent evolution that led to the rise of these mutated strains at different geographic regions during the Covid-19 pandemic. Furthermore, the book explores how these variants do and may impact the efficacy of established neutralizing antibody-based (nAb) vaccines and therapeutics by analysing latest in vivo and in vitro clinical data. Finally, the author discusses ways on how nAb Covid-19 treatment derived immune escape of SARS-CoV-2 could be minimized in the future. | |
| 988 | _aSpringer_BiomedLife_2021 | ||
| 650 | 7 |
_2embne _aCOVID-19 _9683668 |
|
| 776 | 0 | 8 |
_iPrinted edition: _z9783030873233 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030873257 |
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-87324-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE |
||
| 998 |
_b01/2022 _dz _eb _zSI |
||